Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

348 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Phase II clinical study of modified FOLFOX7 (intermittent oxaliplatin administration) plus bevacizumab in patients with unresectable metastatic colorectal cancer-CRAFT study.
Tezuka T, Hamada C, Ishida H, Ooshiro M, Matsuoka H, Kawasaki S, Mishima H, Maeda K, Sakamoto J, Koda K. Tezuka T, et al. Among authors: koda k. Invest New Drugs. 2013 Oct;31(5):1321-9. doi: 10.1007/s10637-013-9982-3. Epub 2013 Jul 2. Invest New Drugs. 2013. PMID: 23817973 Free PMC article. Clinical Trial.
Efficacy and safety of neoadjuvant chemotherapy with oxaliplatin, 5-fluorouracil, and levofolinate for T3 or T4 stage II/III rectal cancer: the FACT trial.
Koike J, Funahashi K, Yoshimatsu K, Yokomizo H, Kan H, Yamada T, Ishida H, Ishibashi K, Saida Y, Enomoto T, Katsumata K, Hisada M, Hasegawa H, Koda K, Ochiai T, Sakamoto K, Shiokawa H, Ogawa S, Itabashi M, Kameoka S. Koike J, et al. Among authors: koda k. Cancer Chemother Pharmacol. 2017 Mar;79(3):519-525. doi: 10.1007/s00280-017-3243-7. Epub 2017 Feb 1. Cancer Chemother Pharmacol. 2017. PMID: 28150022 Clinical Trial.
Safety of mFOLFOX6/XELOX as adjuvant chemotherapy after curative resection of stage III colon cancer: phase II clinical study (The FACOS study).
Kosugi C, Koda K, Ishibashi K, Yoshimatsu K, Tanaka S, Kato R, Kato H, Oya M, Narushima K, Mori M, Shuto K, Ishida H. Kosugi C, et al. Among authors: koda k. Int J Colorectal Dis. 2018 Jun;33(6):809-817. doi: 10.1007/s00384-018-2979-9. Epub 2018 Feb 27. Int J Colorectal Dis. 2018. PMID: 29484450 Clinical Trial.
A Japanese multicenter phase II study of adjuvant chemotherapy with mFOLFOX6/CAPOX for stage III colon cancer treatment after D2/D3 lymphadenectomy.
Yoshimatsu K, Ishibashi K, Koda K, Yokomizo H, Oda N, Oshiro M, Kato H, Oya M, Nakajima H, Ooki S, Maekawa H, Matsunami T, Tsubaki M, Yamada T, Kobayashi M, Tanakaya K, Yokoyama M, Ishida H. Yoshimatsu K, et al. Among authors: koda k. Surg Today. 2019 Jun;49(6):498-506. doi: 10.1007/s00595-019-1771-y. Epub 2019 Apr 5. Surg Today. 2019. PMID: 30953164 Clinical Trial.
Expressions of 10 genes as candidate predictors of recurrence in stage III colon cancer patients receiving adjuvant oxaliplatin-based chemotherapy.
Kumamoto K, Nakachi Y, Mizuno Y, Yokoyama M, Ishibashi K, Kosugi C, Koda K, Kobayashi M, Tanakaya K, Matsunami T, Eguchi H, Okazaki Y, Ishida H. Kumamoto K, et al. Among authors: koda k. Oncol Lett. 2019 Aug;18(2):1388-1394. doi: 10.3892/ol.2019.10437. Epub 2019 Jun 5. Oncol Lett. 2019. PMID: 31423202 Free PMC article.
A Trial Protocol of Biweekly TAS-102 and Bevacizumab as Third-Line Chemotherapy for Advanced/Recurrent Colorectal Cancer: A Phase II Multicenter Clinical Trial (The TAS-CC4 Study).
Yoshida Y, Yamada T, Matsuoka H, Sonoda H, Fukazawa A, Yoshida H, Ishida H, Hirata K, Hasegawa S, Sakamoto K, Otsuka T, Koda K. Yoshida Y, et al. Among authors: koda k. J Anus Rectum Colon. 2019 Jul 30;3(3):136-141. doi: 10.23922/jarc.2018-043. eCollection 2019. J Anus Rectum Colon. 2019. PMID: 31583329 Free PMC article.
348 results